🇺🇸 FDA
Pipeline program

TNFα Monoclonal Antibody

2021070701

Phase 2 small_molecule active

Quick answer

TNFα Monoclonal Antibody for Spinal Cord Injuries is a Phase 2 program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Spinal Cord Injuries
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials